A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis
Phase of Trial: Phase III
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Fibrosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms AURORA; STELLARIS
- Sponsors Tobira Therapeutics
- 30 Nov 2017 Planned End Date changed from 31 Oct 2024 to 31 Jul 2024.
- 07 Apr 2017 Status changed from not yet recruiting to recruiting.
- 18 Jan 2017 Status changed from planning to not yet recruiting.